Credit Suisse AG decreased its position in Masimo Co. (NASDAQ:MASI) by 14.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,632 shares of the medical equipment provider’s stock after selling 15,465 shares during the period. Credit Suisse AG owned approximately 0.18% of Masimo worth $11,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. acquired a new stake in Masimo during the 2nd quarter worth about $109,000. CIBC Asset Management Inc acquired a new stake in Masimo during the 3rd quarter worth about $227,000. Parametrica Management Ltd acquired a new stake in Masimo during the 3rd quarter worth about $234,000. US Bancorp DE grew its position in Masimo by 36.9% during the 2nd quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock worth $193,000 after purchasing an additional 534 shares during the period. Finally, Personal Capital Advisors Corp acquired a new stake in Masimo during the 3rd quarter worth about $251,000. Institutional investors own 82.74% of the company’s stock.
Several equities research analysts have weighed in on MASI shares. Stifel Nicolaus increased their price target on Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. Needham & Company LLC assumed coverage on Masimo in a research report on Friday, September 14th. They set a “buy” rating on the stock. BidaskClub cut Masimo from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 3rd. UBS Group assumed coverage on Masimo in a research report on Tuesday, November 27th. They set a “buy” rating and a $137.00 target price on the stock. Finally, Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research report on Monday, November 26th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $119.00.
In related news, Director Sanford Fitch sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $110.90, for a total value of $221,800.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Anand Sampath sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $110.00, for a total transaction of $3,300,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 309,180 shares of company stock worth $37,570,849 over the last 90 days. Insiders own 12.60% of the company’s stock.
NASDAQ:MASI opened at $105.30 on Friday. Masimo Co. has a 52 week low of $80.69 and a 52 week high of $126.89. The stock has a market cap of $5.74 billion, a PE ratio of 42.98, a price-to-earnings-growth ratio of 2.38 and a beta of 1.07.
Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.02. Masimo had a return on equity of 20.29% and a net margin of 17.08%. The firm had revenue of $210.58 million for the quarter, compared to analysts’ expectations of $207.62 million. During the same period last year, the firm earned $0.56 EPS. The company’s quarterly revenue was up 8.9% on a year-over-year basis. Analysts predict that Masimo Co. will post 2.92 earnings per share for the current fiscal year.
WARNING: “Masimo Co. (MASI) Shares Sold by Credit Suisse AG” was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/12/08/masimo-co-masi-shares-sold-by-credit-suisse-ag.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Recommended Story: What is a stock split?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.